Please sign in to follow a disease.
Ovarian Brenner tumor
MONDO:0002370A benign, borderline, or malignant transitional cell neoplasm arising from the ovary. It constitutes between 1% and 2% of all ovarian neoplasms. The average age at presentation is about 50 years. Grossly it is usually unilateral, firm and white or yellowish. Microscopically it consists of solid and cystic nests of epithelial cells resembling transitional epithelium surrounded by an abundant stromal component of dense, fibroblastic nature.
Also known as: Brenner tumor, Brenner tumour, Brenner neoplasm of ovary, Brenner neoplasm of the ovary, Brenner tumor of ovary, Brenner tumor of the ovary, Brenner tumour of ovary, Brenner tumour of the ovary
1438 clinical trials for this condition and its sub-types, 3 tagged with Ovarian Brenner tumor itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Ovarian Brenner tumor
-
Malignant ovarian Brenner tumor 2 trials
-
New drug combo shows promise for tough ovarian cancers
Disease control OngoingThis study tests whether adding an experimental drug (AZD1775) to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 124 women will be randomly assigned to receive eith…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Weekly vs. Every-3-Weeks chemo: which works better for ovarian cancer?
Disease control OngoingThis phase III trial tested two different schedules of the chemotherapy drug paclitaxel (weekly vs. every three weeks) combined with carboplatin, with or without the targeted drug bevacizumab, in 692 patients with advanced ovarian, peritoneal, or fallopian tube cancer. The goal w…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for recurrent ovarian cancer: drug combo and surgery may extend life
Disease control OngoingThis study looked at adding the drug bevacizumab to standard chemotherapy (carboplatin and paclitaxel or gemcitabine) and surgery for people with ovarian, peritoneal, or fallopian tube cancer that came back after initial treatment. Over 1,000 participants were randomly assigned t…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC